Boehringer Ingelheim Pharmaceuticals Issues Public Comment on FDA Notice
2020-02-18
zz-Public Comments2020-02-18
Targeted News Service
WASHINGTON, Feb. 18 -- Jeffrey R. Snyder, executive director and interim head for regulatory affairs at Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, has issued a public comment . . .
TARGETED NEWS SERVICE (founded 2004) features non-partisan 'edited journalism' news briefs and information for news organizations, public policy groups and other organizations. For more information contact MYRON STRUCK, editor, editor@targetednews.com, Springfield, Virginia; 703/304-1897; https://targetednews.com
WASHINGTON, Feb. 18 -- Jeffrey R. Snyder, executive director and interim head for regulatory affairs at Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, has issued a public comment . . .
TARGETED NEWS SERVICE (founded 2004) features non-partisan 'edited journalism' news briefs and information for news organizations, public policy groups and other organizations. For more information contact MYRON STRUCK, editor, editor@targetednews.com, Springfield, Virginia; 703/304-1897; https://targetednews.com
Copyright © Targeted News Service, 2020